Karuna Therapeutics Inc., of Boston, said it closed its IPO of about 6.4 million shares, which includes the full exercise of the underwriters' overallotment of 836,718 shares, priced at $16 per share. Gross proceeds were about $102.6 million.

Morphic Holding Inc., of Waltham, Mass., said it closed its IPO of 6.9 million common shares, including 900,000 shares sold for the full exercise of overallotments, at $15 apiece to raise $103.5 million. 

LONDON – Two new $250 million investment funds have been announced, promising long-term capital to new companies formed around the U.K.'s science base. Ahren Innovation Capital LP, which is supported by eight of Cambridge University's most prominent scientists – including two Nobel laureates – has closed at $250 million. Meanwhile, SV Health Investors announced the launch of its $250 million seventh fund, with the charity Cancer Research UK (CRUK) putting in $25 million as cornerstone investor.

CNS Pharmaceuticals Inc., of Houston, filed an S-1 with the SEC for a proposed IPO to raise about $10 million by offering 2.1 million shares priced at $4 to $5 per share. Founded in 2017, CNS Pharmaceuticals is developing therapies for brain cancer and other central nervous system tumors. It is seeking a listing on Nasdaq under the ticker CNSP.

Century Therapeutics Inc. came out of stealth mode Monday with $250 million in funding commitments from lead investor Bayer AG, founding investor Versant Ventures and strategic partner Fujifilm Holdings Corp. to develop next-generation allogeneic cell therapies for cancer, based on induced pluripotent stem cells (iPSCs).

Mirati Therapeutics Inc., of San Diego, raised gross proceeds of $234.2 million in a now-closed underwritten public offering of about 2.4 million common shares priced at $97 each. Underwriters of the offering exercised in full their option to purchase up to 315,000 additional shares. Cowen, Credit Suisse and Barclays acted as joint book-running managers.